BACKGROUND AND OBJECTIVE: The major cause of failure in the management of @entity995 is the persistence/recurrence of vitreous seeds (VS). This study reports the efficacy and complications of standard lower-dose (20   g) intravitreal melphalan for VS. @entity1 AND METHODS: Retrospective review of all @entity1 with active VS treated with lower-dose intravitreal melphalan (20   g/0.1 mL) on a monthly basis until complete VS regression was achieved. RESULTS: A total of 14 injections were delivered to seven eyes of seven @entity1 (range: 1-4; median: 2). At a median follow-up of 20 months (range: 12-32 months), complete regression of VS was achieved in all cases (100%), and globe salvage was achieved in six cases (86%). One eye required enucleation for solid @entity5 recurrence. Side effects of retinal pigment epithelium mottling at the site of injection was noted in two eyes (29%). CONCLUSION: The 2-year results of this study suggest that standard lower-dose (20   g) intravitreal melphalan is safe and highly effective for the management of viable VS from @entity995 . [Ophthalmic Surg Lasers Imaging Retina. 2015;46:942-948.].

Intravitreal Lower-Dose (20   g) Melphalan for Persistent or Recurrent XXXX Vitreous Seeds.

@entity1 :: ('9606', 'Species') :: ['PATIENTS', 'patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity995 :: ('MESH:D012175', 'Disease') :: ['retinoblastoma']
@entity995 :: (MESH:D012175,Disease) :: ['Retinoblastoma']
